Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma

B‐cell non‐Hodgkin lymphoma (B‐NHL) is the most frequent hematological malignancy. Although refined chemotherapy regimens and several new therapeutics including rituximab, a chimeric anti‐CD20 monoclonal antibody, have improved its prognosis in recent decades, there are still a substantial number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Makita, Shinichi, Yoshimura, Kiyoshi, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480083/
https://www.ncbi.nlm.nih.gov/pubmed/28301076
http://dx.doi.org/10.1111/cas.13239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480083/
https://www.ncbi.nlm.nih.gov/pubmed/28301076
http://dx.doi.org/10.1111/cas.13239

Ejemplares similares